Dapiprazole

DB00298ApprovedSmall moleculeAdrenergic alpha-Antagonists

Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.

Mechanism: Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.
Curator reviewed
Primary indication: Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.Curator reviewed · 1 structured indication
Formula / weight: C₁₉H₂₇N₅ · 325.4512 g/mol (avg)
First approval: United States, 2019

Resolves to

Compound

UNII5RNZ8GJO7KCAS72822-12-9ChEMBLCHEMBL1201216ChEBI51066PubChem3033538KEGGD07775

Clinical / RWD

RxNorm22298ATCS01EX02PharmGKBPA164749109

Structure

InChIKeyRFWZESUMWJKKRN-UHFFFAOYSA-NSMILESCC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1

Targets

P35348ADRA1AP25100ADRA1DP35368ADRA1BP14416DRD2

What you can answer from here — as of September 16, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

21Drug interactionsStructured to mechanism, not free text

1Structured indicationCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

3Marketed productsAcross 2 countries and 2 labellers

1ATC codeIncluding every combination product, plus 15 drug categories

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dapiprazole, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In